INDICATOR_ID	INDICATOR_NUM	INDICATOR_DESC	MINSET_SERIES	MINSET_SERIES_DESC	REF_AREA	REF_AREA_DESC	ISO3	X	Y	SDG_REGION	TIME_PERIOD	SEX	SEX_DESC	OBS_VALUE_MODIFIER	OBS_VALUE	UNIT_MEASURE	UNIT_MEASURE_DESC	NATURE	NATURE_DESC	REPORTING_TYPE	REPORTING_TYPE_DESC	LOWER_BOUND_MODIFIER	LOWER_BOUND	UPPER_BOUND_MODIFIER	UPPER_BOUND	SOURCE_YEAR
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2018.0	F	Female		12.0	PT	Percent	E	Estimated	G	Global		7.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2018.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		7.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2018.0	F	Female		83.0	PT	Percent	E	Estimated	G	Global		78.0		88.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2018.0	M	Male		74.0	PT	Percent	E	Estimated	G	Global		66.0		81.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2018.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		24.0		32.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2018.0	M	Male		30.0	PT	Percent	E	Estimated	G	Global		26.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2018.0	F	Female		69.0	PT	Percent	E	Estimated	G	Global		63.0		75.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2018.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		50.0		63.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2018.0	F	Female		83.0	PT	Percent	E	Estimated	G	Global		72.0		91.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2018.0	M	Male		82.0	PT	Percent	E	Estimated	G	Global		69.0		94.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2018.0	F	Female		58.0	PT	Percent	E	Estimated	G	Global		51.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2018.0	M	Male		49.0	PT	Percent	E	Estimated	G	Global		42.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	48.0	Bahrain	BHR	50.5490754	26.04407747	Northern Africa and Western Asia	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		57.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	48.0	Bahrain	BHR	50.5490754	26.04407747	Northern Africa and Western Asia	2018.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		57.0		75.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2018.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		18.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2018.0	M	Male		22.0	PT	Percent	E	Estimated	G	Global		20.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2018.0	F	Female		56.0	PT	Percent	E	Estimated	G	Global		47.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2018.0	M	Male		51.0	PT	Percent	E	Estimated	G	Global		42.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2018.0	F	Female		62.0	PT	Percent	E	Estimated	G	Global		56.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		38.0		51.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	64.0	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2018.0	F	Female		57.0	PT	Percent	E	Estimated	G	Global		32.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	64.0	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2018.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		13.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2018.0	F	Female		44.0	PT	Percent	E	Estimated	G	Global		41.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		39.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2018.0	F	Female		85.0	PT	Percent	E	Estimated	G	Global		75.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2018.0	M	Male		64.0	PT	Percent	E	Estimated	G	Global		52.0		75.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2018.0	F	Female	>	95.0	PT	Percent	E	Estimated	G	Global		86.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2018.0	M	Male		71.0	PT	Percent	E	Estimated	G	Global		64.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2018.0	F	Female		29.0	PT	Percent	E	Estimated	G	Global		26.0		32.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2018.0	M	Male		27.0	PT	Percent	E	Estimated	G	Global		24.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2018.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		29.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2018.0	M	Male		43.0	PT	Percent	E	Estimated	G	Global		37.0		50.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2018.0	F	Female		81.0	PT	Percent	E	Estimated	G	Global		73.0		91.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2018.0	M	Male		63.0	PT	Percent	E	Estimated	G	Global		56.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2018.0	F	Female		93.0	PT	Percent	E	Estimated	G	Global		81.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2018.0	M	Male		78.0	PT	Percent	E	Estimated	G	Global		67.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2018.0	F	Female		61.0	PT	Percent	E	Estimated	G	Global		49.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2018.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		46.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2018.0	F	Female		82.0	PT	Percent	E	Estimated	G	Global		72.0		93.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2018.0	M	Male		80.0	PT	Percent	E	Estimated	G	Global		68.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2018.0	F	Female		59.0	PT	Percent	E	Estimated	G	Global		52.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2018.0	M	Male		47.0	PT	Percent	E	Estimated	G	Global		41.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2018.0	F	Female		94.0	PT	Percent	E	Estimated	G	Global		79.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2018.0	M	Male		81.0	PT	Percent	E	Estimated	G	Global		68.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2018.0	F	Female		44.0	PT	Percent	E	Estimated	G	Global		36.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2018.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		23.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2018.0	F	Female		45.0	PT	Percent	E	Estimated	G	Global		40.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		39.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2018.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		53.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2018.0	M	Male		42.0	PT	Percent	E	Estimated	G	Global		33.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2018.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		48.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2018.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		56.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2018.0	F	Female		77.0	PT	Percent	E	Estimated	G	Global		64.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2018.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		59.0		88.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2018.0	F	Female		63.0	PT	Percent	E	Estimated	G	Global		33.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2018.0	M	Male	>	95.0	PT	Percent	E	Estimated	G	Global		50.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2018.0	F	Female		36.0	PT	Percent	E	Estimated	G	Global		27.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2018.0	M	Male		36.0	PT	Percent	E	Estimated	G	Global		28.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2018.0	F	Female		58.0	PT	Percent	E	Estimated	G	Global		47.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2018.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		60.0		85.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2018.0	F	Female		60.0	PT	Percent	E	Estimated	G	Global		54.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2018.0	M	Male		46.0	PT	Percent	E	Estimated	G	Global		40.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		59.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2018.0	M	Male		76.0	PT	Percent	E	Estimated	G	Global		68.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2018.0	F	Female		80.0	PT	Percent	E	Estimated	G	Global		61.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2018.0	M	Male		70.0	PT	Percent	E	Estimated	G	Global		54.0		83.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2018.0	F	Female		60.0	PT	Percent	E	Estimated	G	Global		54.0		67.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2018.0	M	Male		60.0	PT	Percent	E	Estimated	G	Global		50.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2018.0	F	Female		77.0	PT	Percent	E	Estimated	G	Global		51.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2018.0	M	Male		38.0	PT	Percent	E	Estimated	G	Global		25.0		61.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2018.0	F	Female		90.0	PT	Percent	E	Estimated	G	Global		80.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2018.0	M	Male		88.0	PT	Percent	E	Estimated	G	Global		78.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2018.0	F	Female		60.0	PT	Percent	E	Estimated	G	Global		47.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2018.0	M	Male		51.0	PT	Percent	E	Estimated	G	Global		38.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2018.0	F	Female		62.0	PT	Percent	E	Estimated	G	Global		42.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2018.0	M	Male		55.0	PT	Percent	E	Estimated	G	Global		36.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2018.0	F	Female		52.0	PT	Percent	E	Estimated	G	Global		43.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		36.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2018.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		43.0		68.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2018.0	M	Male		18.0	PT	Percent	E	Estimated	G	Global		14.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		50.0		85.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2018.0	M	Male		66.0	PT	Percent	E	Estimated	G	Global		51.0		86.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2018.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		40.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2018.0	M	Male		50.0	PT	Percent	E	Estimated	G	Global		37.0		67.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2018.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		59.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2018.0	M	Male		55.0	PT	Percent	E	Estimated	G	Global		47.0		61.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2018.0	F	Female		76.0	PT	Percent	E	Estimated	G	Global		58.0		94.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2018.0	M	Male		76.0	PT	Percent	E	Estimated	G	Global		59.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2018.0	F	Female		75.0	PT	Percent	E	Estimated	G	Global		65.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2018.0	M	Male		85.0	PT	Percent	E	Estimated	G	Global		69.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2018.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		28.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2018.0	M	Male		30.0	PT	Percent	E	Estimated	G	Global		24.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		52.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2018.0	M	Male		74.0	PT	Percent	E	Estimated	G	Global		59.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2018.0	F	Female		48.0	PT	Percent	E	Estimated	G	Global		41.0		56.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2018.0	M	Male		50.0	PT	Percent	E	Estimated	G	Global		43.0		58.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2018.0	F	Female		37.0	PT	Percent	E	Estimated	G	Global		30.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2018.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		14.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2018.0	F	Female		74.0	PT	Percent	E	Estimated	G	Global		66.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2018.0	M	Male		81.0	PT	Percent	E	Estimated	G	Global		64.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2018.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		34.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2018.0	M	Male		25.0	PT	Percent	E	Estimated	G	Global		21.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2018.0	F	Female		38.0	PT	Percent	E	Estimated	G	Global		35.0		42.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2018.0	M	Male		47.0	PT	Percent	E	Estimated	G	Global		43.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2018.0	F	Female		50.0	PT	Percent	E	Estimated	G	Global		42.0		59.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2018.0	M	Male		30.0	PT	Percent	E	Estimated	G	Global		25.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2018.0	F	Female		78.0	PT	Percent	E	Estimated	G	Global		68.0		88.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2018.0	M	Male		61.0	PT	Percent	E	Estimated	G	Global		52.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2018.0	F	Female		63.0	PT	Percent	E	Estimated	G	Global		57.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2018.0	M	Male		52.0	PT	Percent	E	Estimated	G	Global		47.0		61.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2018.0	F	Female		61.0	PT	Percent	E	Estimated	G	Global		49.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		34.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2018.0	F	Female		41.0	PT	Percent	E	Estimated	G	Global		36.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2018.0	M	Male		58.0	PT	Percent	E	Estimated	G	Global		50.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2018.0	F	Female	>	95.0	PT	Percent	E	Estimated	G	Global		85.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2018.0	M	Male		74.0	PT	Percent	E	Estimated	G	Global		65.0		81.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2018.0	F	Female		17.0	PT	Percent	E	Estimated	G	Global		15.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2018.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		15.0		20.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2018.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		16.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2018.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		9.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2018.0	F	Female		76.0	PT	Percent	E	Estimated	G	Global		68.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2018.0	M	Male		81.0	PT	Percent	E	Estimated	G	Global		69.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2018.0	F	Female		90.0	PT	Percent	E	Estimated	G	Global		77.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2018.0	M	Male		92.0	PT	Percent	E	Estimated	G	Global		75.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2018.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		53.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2018.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		31.0		50.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2018.0	F	Female		47.0	PT	Percent	E	Estimated	G	Global		42.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2018.0	M	Male		22.0	PT	Percent	E	Estimated	G	Global		19.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2018.0	F	Female		80.0	PT	Percent	E	Estimated	G	Global		71.0		89.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2018.0	M	Male		80.0	PT	Percent	E	Estimated	G	Global		67.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2018.0	F	Female		69.0	PT	Percent	E	Estimated	G	Global		64.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2018.0	M	Male		51.0	PT	Percent	E	Estimated	G	Global		46.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2018.0	F	Female		75.0	PT	Percent	E	Estimated	G	Global		68.0		85.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2018.0	M	Male		87.0	PT	Percent	E	Estimated	G	Global		78.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2018.0	F	Female		75.0	PT	Percent	E	Estimated	G	Global		64.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2018.0	M	Male		59.0	PT	Percent	E	Estimated	G	Global		50.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2018.0	F	Female		52.0	PT	Percent	E	Estimated	G	Global		47.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2018.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		59.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2018.0	F	Female		54.0	PT	Percent	E	Estimated	G	Global		41.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2018.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		25.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2018.0	F	Female		57.0	PT	Percent	E	Estimated	G	Global		51.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2018.0	M	Male		54.0	PT	Percent	E	Estimated	G	Global		47.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2018.0	F	Female		37.0	PT	Percent	E	Estimated	G	Global		33.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2018.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		57.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		61.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2018.0	M	Male		54.0	PT	Percent	E	Estimated	G	Global		49.0		59.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2018.0	F	Female		45.0	PT	Percent	E	Estimated	G	Global		41.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2018.0	M	Male		45.0	PT	Percent	E	Estimated	G	Global		41.0		50.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2018.0	F	Female		45.0	PT	Percent	E	Estimated	G	Global		41.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2018.0	M	Male		25.0	PT	Percent	E	Estimated	G	Global		22.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2018.0	F	Female		47.0	PT	Percent	E	Estimated	G	Global		43.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2018.0	M	Male		43.0	PT	Percent	E	Estimated	G	Global		38.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2018.0	F	Female		78.0	PT	Percent	E	Estimated	G	Global		68.0		87.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2018.0	M	Male		76.0	PT	Percent	E	Estimated	G	Global		66.0		87.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2018.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		12.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2018.0	M	Male		6.0	PT	Percent	E	Estimated	G	Global		5.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2018.0	F	Female		86.0	PT	Percent	E	Estimated	G	Global		78.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2018.0	M	Male		68.0	PT	Percent	E	Estimated	G	Global		61.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2018.0	F	Female		71.0	PT	Percent	E	Estimated	G	Global		62.0		80.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2018.0	M	Male		43.0	PT	Percent	E	Estimated	G	Global		38.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2018.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		28.0		44.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2018.0	M	Male		29.0	PT	Percent	E	Estimated	G	Global		23.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2018.0	F	Female		75.0	PT	Percent	E	Estimated	G	Global		63.0		93.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2018.0	M	Male		41.0	PT	Percent	E	Estimated	G	Global		32.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2018.0	F	Female		19.0	PT	Percent	E	Estimated	G	Global		16.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2018.0	M	Male		23.0	PT	Percent	E	Estimated	G	Global		19.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2018.0	F	Female		30.0	PT	Percent	E	Estimated	G	Global		27.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2018.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		29.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2018.0	F	Female		41.0	PT	Percent	E	Estimated	G	Global		33.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2018.0	M	Male		29.0	PT	Percent	E	Estimated	G	Global		23.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2018.0	F	Female		38.0	PT	Percent	E	Estimated	G	Global		32.0		44.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2018.0	M	Male		41.0	PT	Percent	E	Estimated	G	Global		33.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2018.0	F	Female		76.0	PT	Percent	E	Estimated	G	Global		62.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2018.0	M	Male		54.0	PT	Percent	E	Estimated	G	Global		42.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2018.0	F	Female		64.0	PT	Percent	E	Estimated	G	Global		51.0		77.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2018.0	M	Male		42.0	PT	Percent	E	Estimated	G	Global		33.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2018.0	F	Female		44.0	PT	Percent	E	Estimated	G	Global		40.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2018.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		34.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2018.0	F	Female	>	95.0	PT	Percent	E	Estimated	G	Global	>	95.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2018.0	M	Male		77.0	PT	Percent	E	Estimated	G	Global		70.0		83.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2018.0	F	Female		66.0	PT	Percent	E	Estimated	G	Global		58.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2018.0	M	Male		47.0	PT	Percent	E	Estimated	G	Global		41.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2018.0	F	Female		71.0	PT	Percent	E	Estimated	G	Global		62.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2018.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		60.0		86.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2018.0	F	Female		54.0	PT	Percent	E	Estimated	G	Global		44.0		68.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2018.0	M	Male		53.0	PT	Percent	E	Estimated	G	Global		43.0		68.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2018.0	F	Female		69.0	PT	Percent	E	Estimated	G	Global		58.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2018.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		32.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2018.0	F	Female		68.0	PT	Percent	E	Estimated	G	Global		51.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2018.0	M	Male		37.0	PT	Percent	E	Estimated	G	Global		28.0		51.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2018.0	F	Female		82.0	PT	Percent	E	Estimated	G	Global		74.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2018.0	M	Male		82.0	PT	Percent	E	Estimated	G	Global		74.0		90.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2018.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2018.0	M	Male		11.0	PT	Percent	E	Estimated	G	Global		10.0		12.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2018.0	F	Female		45.0	PT	Percent	E	Estimated	G	Global		41.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2018.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		50.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2018.0	F	Female		70.0	PT	Percent	E	Estimated	G	Global		63.0		77.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2018.0	M	Male		61.0	PT	Percent	E	Estimated	G	Global		54.0		67.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2018.0	F	Female		43.0	PT	Percent	E	Estimated	G	Global		33.0		61.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2018.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		29.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2018.0	F	Female		78.0	PT	Percent	E	Estimated	G	Global		58.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2018.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		53.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2018.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		19.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2018.0	M	Male		45.0	PT	Percent	E	Estimated	G	Global		38.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2018.0	F	Female		91.0	PT	Percent	E	Estimated	G	Global		80.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2018.0	M	Male		90.0	PT	Percent	E	Estimated	G	Global		76.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2018.0	F	Female		49.0	PT	Percent	E	Estimated	G	Global		43.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2018.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		15.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2018.0	F	Female		72.0	PT	Percent	E	Estimated	G	Global		64.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2018.0	M	Male		64.0	PT	Percent	E	Estimated	G	Global		55.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2018.0	F	Female		91.0	PT	Percent	E	Estimated	G	Global		80.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2018.0	M	Male		84.0	PT	Percent	E	Estimated	G	Global		73.0		94.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2018.0	F	Female		72.0	PT	Percent	E	Estimated	G	Global		63.0		81.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2018.0	M	Male		58.0	PT	Percent	E	Estimated	G	Global		50.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		47.0		83.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2018.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		46.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2018.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		42.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2018.0	M	Male		29.0	PT	Percent	E	Estimated	G	Global		22.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2018.0	F	Female		48.0	PT	Percent	E	Estimated	G	Global		37.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2018.0	M	Male		55.0	PT	Percent	E	Estimated	G	Global		39.0		87.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2018.0	F	Female		68.0	PT	Percent	E	Estimated	G	Global		60.0		76.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2018.0	M	Male		63.0	PT	Percent	E	Estimated	G	Global		54.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2018.0	F	Female		32.0	PT	Percent	E	Estimated	G	Global		24.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2018.0	M	Male		32.0	PT	Percent	E	Estimated	G	Global		25.0		42.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2018.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		60.0		70.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2018.0	M	Male		56.0	PT	Percent	E	Estimated	G	Global		50.0		60.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2018.0	F	Female		93.0	PT	Percent	E	Estimated	G	Global		81.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2018.0	M	Male		83.0	PT	Percent	E	Estimated	G	Global		72.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2018.0	F	Female		84.0	PT	Percent	E	Estimated	G	Global		75.0		92.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2018.0	M	Male		84.0	PT	Percent	E	Estimated	G	Global		72.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2018.0	F	Female		19.0	PT	Percent	E	Estimated	G	Global		14.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2018.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		10.0		17.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2018.0	F	Female		15.0	PT	Percent	E	Estimated	G	Global		7.0		29.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2018.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		7.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2018.0	F	Female		62.0	PT	Percent	E	Estimated	G	Global		41.0		89.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2018.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		30.0		63.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2018.0	F	Female		91.0	PT	Percent	E	Estimated	G	Global		85.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2018.0	M	Male		79.0	PT	Percent	E	Estimated	G	Global		73.0		87.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2018.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		18.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2018.0	M	Male		20.0	PT	Percent	E	Estimated	G	Global		18.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2018.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		56.0		81.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2018.0	M	Male		32.0	PT	Percent	E	Estimated	G	Global		26.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2018.0	F	Female		77.0	PT	Percent	E	Estimated	G	Global		67.0		88.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2018.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		65.0		85.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2018.0	F	Female		72.0	PT	Percent	E	Estimated	G	Global		67.0		79.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2018.0	M	Male		49.0	PT	Percent	E	Estimated	G	Global		45.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2018.0	F	Female		49.0	PT	Percent	E	Estimated	G	Global		32.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2018.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		20.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2018.0	F	Female		79.0	PT	Percent	E	Estimated	G	Global		74.0		86.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2018.0	M	Male		63.0	PT	Percent	E	Estimated	G	Global		58.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2018.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		62.0		72.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2018.0	M	Male		43.0	PT	Percent	E	Estimated	G	Global		40.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2018.0	F	Female		41.0	PT	Percent	E	Estimated	G	Global		36.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2018.0	M	Male		55.0	PT	Percent	E	Estimated	G	Global		48.0		65.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2018.0	F	Female		25.0	PT	Percent	E	Estimated	G	Global		23.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2018.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		29.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2018.0	F	Female		82.0	PT	Percent	E	Estimated	G	Global		74.0		89.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2018.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		50.0		63.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	854.0	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2018.0	F	Female		80.0	PT	Percent	E	Estimated	G	Global		65.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	854.0	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2018.0	M	Male		46.0	PT	Percent	E	Estimated	G	Global		37.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2018.0	F	Female		73.0	PT	Percent	E	Estimated	G	Global		54.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2018.0	M	Male		51.0	PT	Percent	E	Estimated	G	Global		35.0		69.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2018.0	F	Female		68.0	PT	Percent	E	Estimated	G	Global		63.0		73.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2018.0	M	Male		34.0	PT	Percent	E	Estimated	G	Global		31.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2018.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		22.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2018.0	M	Male		16.0	PT	Percent	E	Estimated	G	Global		9.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2018.0	F	Female		83.0	PT	Percent	E	Estimated	G	Global		75.0		94.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2018.0	M	Male		69.0	PT	Percent	E	Estimated	G	Global		61.0		80.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2010.0	F	Female		6.0	PT	Percent	E	Estimated	G	Global		5.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	68.0	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2010.0	M	Male		5.0	PT	Percent	E	Estimated	G	Global		5.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		24.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	132.0	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2010.0	F	Female		29.0	PT	Percent	E	Estimated	G	Global		25.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2010.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2000.0	M	Male		2.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2010.0	F	Female		2.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	728.0	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2010.0	M	Male		2.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2010.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	4.0	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2010.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	450.0	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2010.0	F	Female		2.0	PT	Percent	E	Estimated	G	Global		2.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2010.0	F	Female		2.0	PT	Percent	E	Estimated	G	Global		2.0		2.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2000.0	F	Female		2.0	PT	Percent	E	Estimated	G	Global	<	1.0		3.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2000.0	F	Female		3.0	PT	Percent	E	Estimated	G	Global		2.0		3.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2010.0	M	Male		3.0	PT	Percent	E	Estimated	G	Global		2.0		3.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2000.0	F	Female		2.0	PT	Percent	E	Estimated	G	Global		2.0		3.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2010.0	M	Male		4.0	PT	Percent	E	Estimated	G	Global		3.0		4.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2010.0	F	Female		4.0	PT	Percent	E	Estimated	G	Global		3.0		4.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	586.0	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2010.0	M	Male		3.0	PT	Percent	E	Estimated	G	Global		3.0		4.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2010.0	F	Female		4.0	PT	Percent	E	Estimated	G	Global		3.0		5.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2010.0	M	Male		4.0	PT	Percent	E	Estimated	G	Global		3.0		5.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2010.0	M	Male		3.0	PT	Percent	E	Estimated	G	Global		3.0		5.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	360.0	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2010.0	F	Female		4.0	PT	Percent	E	Estimated	G	Global		4.0		5.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2010.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		11.0		17.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	364.0	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2010.0	F	Female		4.0	PT	Percent	E	Estimated	G	Global		3.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2010.0	F	Female		5.0	PT	Percent	E	Estimated	G	Global		4.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2000.0	M	Male		5.0	PT	Percent	E	Estimated	G	Global		4.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2010.0	M	Male		4.0	PT	Percent	E	Estimated	G	Global		4.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	384.0	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		18.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2010.0	M	Male		5.0	PT	Percent	E	Estimated	G	Global		5.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2010.0	M	Male		5.0	PT	Percent	E	Estimated	G	Global		5.0		6.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	64.0	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2010.0	M	Male		3.0	PT	Percent	E	Estimated	G	Global	<	1.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2010.0	M	Male		6.0	PT	Percent	E	Estimated	G	Global		5.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2010.0	F	Female		6.0	PT	Percent	E	Estimated	G	Global		5.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	706.0	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2010.0	M	Male		6.0	PT	Percent	E	Estimated	G	Global		5.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	729.0	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2010.0	M	Male		6.0	PT	Percent	E	Estimated	G	Global		5.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2010.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		6.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2010.0	M	Male		6.0	PT	Percent	E	Estimated	G	Global		6.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2000.0	F	Female		6.0	PT	Percent	E	Estimated	G	Global		6.0		7.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	50.0	Bangladesh	BGD	89.17660788	22.86961622	Central and Southern Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2000.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	480.0	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2010.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	496.0	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2000.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2000.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	762.0	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		7.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	860.0	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		7.0		8.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2010.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		6.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2000.0	F	Female		9.0	PT	Percent	E	Estimated	G	Global		8.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2000.0	M	Male		9.0	PT	Percent	E	Estimated	G	Global		8.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	417.0	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2010.0	F	Female		7.0	PT	Percent	E	Estimated	G	Global		6.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	51.0	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2010.0	M	Male		9.0	PT	Percent	E	Estimated	G	Global		7.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2010.0	F	Female		9.0	PT	Percent	E	Estimated	G	Global		7.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	226.0	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2010.0	F	Female		8.0	PT	Percent	E	Estimated	G	Global		7.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	818.0	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2010.0	M	Male		9.0	PT	Percent	E	Estimated	G	Global		8.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	144.0	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2010.0	F	Female		9.0	PT	Percent	E	Estimated	G	Global		8.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2010.0	M	Male		9.0	PT	Percent	E	Estimated	G	Global		9.0		10.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	498.0	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2010.0	M	Male		8.0	PT	Percent	E	Estimated	G	Global		6.0		11.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2010.0	F	Female		10.0	PT	Percent	E	Estimated	G	Global		8.0		11.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2000.0	F	Female		10.0	PT	Percent	E	Estimated	G	Global		9.0		11.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	398.0	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2010.0	F	Female		10.0	PT	Percent	E	Estimated	G	Global		10.0		11.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2010.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		10.0		12.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2010.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		9.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2010.0	F	Female		12.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	430.0	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2000.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2010.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2010.0	M	Male		11.0	PT	Percent	E	Estimated	G	Global		10.0		13.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2000.0	M	Male		7.0	PT	Percent	E	Estimated	G	Global		5.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2010.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		9.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	270.0	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2010.0	M	Male		11.0	PT	Percent	E	Estimated	G	Global		9.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2010.0	F	Female		11.0	PT	Percent	E	Estimated	G	Global		9.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	694.0	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2010.0	M	Male		11.0	PT	Percent	E	Estimated	G	Global		9.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2010.0	F	Female		12.0	PT	Percent	E	Estimated	G	Global		10.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	140.0	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		10.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2000.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		10.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2000.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		11.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	624.0	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		11.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	428.0	Latvia	LVA	26.42461876	56.64196636	Europe and Northern America	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		11.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	804.0	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2010.0	F	Female		13.0	PT	Percent	E	Estimated	G	Global		13.0		14.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2010.0	M	Male		10.0	PT	Percent	E	Estimated	G	Global		7.0		15.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	262.0	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		9.0		15.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2010.0	F	Female		13.0	PT	Percent	E	Estimated	G	Global		11.0		15.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2000.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		11.0		15.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2010.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		12.0		15.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2010.0	M	Male		12.0	PT	Percent	E	Estimated	G	Global		10.0		16.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	24.0	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2010.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		11.0		16.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2010.0	F	Female		13.0	PT	Percent	E	Estimated	G	Global		11.0		16.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2010.0	M	Male		13.0	PT	Percent	E	Estimated	G	Global		11.0		16.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2010.0	M	Male		35.0	PT	Percent	E	Estimated	G	Global		32.0		39.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2010.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		14.0		17.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	64.0	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2010.0	F	Female		9.0	PT	Percent	E	Estimated	G	Global		4.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2000.0	M	Male		10.0	PT	Percent	E	Estimated	G	Global		7.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	887.0	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2010.0	F	Female		12.0	PT	Percent	E	Estimated	G	Global		8.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	268.0	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2010.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		12.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2010.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		12.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	508.0	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2010.0	F	Female		15.0	PT	Percent	E	Estimated	G	Global		12.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2000.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		12.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	748.0	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2010.0	F	Female		39.0	PT	Percent	E	Estimated	G	Global		36.0		42.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2010.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		13.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	180.0	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2010.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		13.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2010.0	M	Male		15.0	PT	Percent	E	Estimated	G	Global		13.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2000.0	F	Female	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	104.0	Myanmar	MMR	96.51752295	21.19332882	Eastern and South-Eastern Asia	2010.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		14.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	760.0	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2010.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		14.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2010.0	M	Male		16.0	PT	Percent	E	Estimated	G	Global		14.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2000.0	F	Female		10.0	PT	Percent	E	Estimated	G	Global		8.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2000.0	F	Female		17.0	PT	Percent	E	Estimated	G	Global		14.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2010.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		14.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2000.0	F	Female		17.0	PT	Percent	E	Estimated	G	Global		15.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2000.0	M	Male	<	1.0	PT	Percent	E	Estimated	G	Global	<	1.0	<	1.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2010.0	M	Male		14.0	PT	Percent	E	Estimated	G	Global		10.0		20.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2010.0	M	Male		16.0	PT	Percent	E	Estimated	G	Global		13.0		20.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2010.0	M	Male		16.0	PT	Percent	E	Estimated	G	Global		14.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2000.0	F	Female		18.0	PT	Percent	E	Estimated	G	Global		17.0		20.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2010.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		14.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2000.0	M	Male		18.0	PT	Percent	E	Estimated	G	Global		15.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	288.0	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2010.0	M	Male		18.0	PT	Percent	E	Estimated	G	Global		15.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	418.0	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2010.0	F	Female		18.0	PT	Percent	E	Estimated	G	Global		16.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2010.0	M	Male		19.0	PT	Percent	E	Estimated	G	Global		17.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2010.0	M	Male		19.0	PT	Percent	E	Estimated	G	Global		17.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2010.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		18.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2010.0	F	Female		19.0	PT	Percent	E	Estimated	G	Global		18.0		21.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2010.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		13.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2010.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		13.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2010.0	M	Male		20.0	PT	Percent	E	Estimated	G	Global		17.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2010.0	F	Female		19.0	PT	Percent	E	Estimated	G	Global		17.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2010.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		19.0		22.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	600.0	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2010.0	F	Female		16.0	PT	Percent	E	Estimated	G	Global		12.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	524.0	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2010.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		17.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	388.0	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2010.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		18.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2010.0	M	Male		21.0	PT	Percent	E	Estimated	G	Global		18.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	84.0	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2010.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		19.0		23.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2010.0	M	Male		18.0	PT	Percent	E	Estimated	G	Global		13.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	558.0	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2010.0	F	Female		18.0	PT	Percent	E	Estimated	G	Global		15.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2010.0	M	Male		19.0	PT	Percent	E	Estimated	G	Global		16.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2010.0	M	Male		21.0	PT	Percent	E	Estimated	G	Global		18.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	120.0	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2010.0	M	Male		22.0	PT	Percent	E	Estimated	G	Global		19.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2010.0	M	Male		21.0	PT	Percent	E	Estimated	G	Global		19.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	598.0	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2010.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		19.0		24.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	170.0	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		18.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2010.0	M	Male		22.0	PT	Percent	E	Estimated	G	Global		18.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	834.0	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		19.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	332.0	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		20.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2010.0	F	Female		23.0	PT	Percent	E	Estimated	G	Global		21.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	800.0	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2010.0	M	Male		23.0	PT	Percent	E	Estimated	G	Global		21.0		25.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	504.0	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2010.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		16.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		17.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2010.0	F	Female		22.0	PT	Percent	E	Estimated	G	Global		18.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	112.0	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2010.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		18.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	324.0	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2010.0	M	Male		23.0	PT	Percent	E	Estimated	G	Global		19.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	704.0	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2010.0	F	Female		23.0	PT	Percent	E	Estimated	G	Global		20.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2010.0	M	Male		23.0	PT	Percent	E	Estimated	G	Global		21.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	710.0	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2010.0	F	Female		24.0	PT	Percent	E	Estimated	G	Global		22.0		26.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2010.0	M	Male		20.0	PT	Percent	E	Estimated	G	Global		14.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2010.0	M	Male		22.0	PT	Percent	E	Estimated	G	Global		17.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2010.0	F	Female		24.0	PT	Percent	E	Estimated	G	Global		20.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	458.0	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2010.0	F	Female		23.0	PT	Percent	E	Estimated	G	Global		20.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	608.0	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2010.0	F	Female		23.0	PT	Percent	E	Estimated	G	Global		20.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2000.0	F	Female		24.0	PT	Percent	E	Estimated	G	Global		21.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2000.0	F	Female		5.0	PT	Percent	E	Estimated	G	Global		5.0		5.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2000.0	M	Male		18.0	PT	Percent	E	Estimated	G	Global		16.0		19.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2010.0	M	Male		24.0	PT	Percent	E	Estimated	G	Global		21.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2000.0	F	Female		25.0	PT	Percent	E	Estimated	G	Global		23.0		28.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	178.0	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2010.0	M	Male		25.0	PT	Percent	E	Estimated	G	Global		21.0		29.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2010.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		24.0		29.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	512.0	Oman	OMN	57.87743482	21.98805614	Northern Africa and Western Asia	2010.0	F	Female		26.0	PT	Percent	E	Estimated	G	Global		24.0		29.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	214.0	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2010.0	F	Female		23.0	PT	Percent	E	Estimated	G	Global		18.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2000.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		20.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	562.0	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2010.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		23.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	591.0	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2010.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		23.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2010.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		23.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2010.0	M	Male		27.0	PT	Percent	E	Estimated	G	Global		24.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	44.0	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2010.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		24.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2000.0	M	Male		27.0	PT	Percent	E	Estimated	G	Global		24.0		30.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	466.0	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2010.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		20.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2010.0	M	Male		26.0	PT	Percent	E	Estimated	G	Global		22.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		24.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2000.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		25.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	320.0	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		25.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2010.0	F	Female		28.0	PT	Percent	E	Estimated	G	Global		25.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2010.0	M	Male		27.0	PT	Percent	E	Estimated	G	Global		25.0		31.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		23.0		32.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		23.0		32.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2010.0	F	Female		20.0	PT	Percent	E	Estimated	G	Global		13.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		22.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	499.0	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		23.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	108.0	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2010.0	F	Female		29.0	PT	Percent	E	Estimated	G	Global		24.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	422.0	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2010.0	M	Male		29.0	PT	Percent	E	Estimated	G	Global		25.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	768.0	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2010.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		28.0		33.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2010.0	F	Female		25.0	PT	Percent	E	Estimated	G	Global		23.0		27.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	218.0	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2010.0	M	Male		21.0	PT	Percent	E	Estimated	G	Global		13.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2000.0	F	Female		26.0	PT	Percent	E	Estimated	G	Global		20.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2000.0	M	Male		30.0	PT	Percent	E	Estimated	G	Global		24.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2010.0	F	Female		29.0	PT	Percent	E	Estimated	G	Global		24.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2010.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		26.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2010.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		27.0		35.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2010.0	F	Female		27.0	PT	Percent	E	Estimated	G	Global		20.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	434.0	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2010.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		28.0		34.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	854.0	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2010.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		25.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2000.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		25.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2000.0	M	Male		31.0	PT	Percent	E	Estimated	G	Global		26.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	348.0	Hungary	HUN	19.41221519	47.1651448	Europe and Northern America	2000.0	F	Female		31.0	PT	Percent	E	Estimated	G	Global		27.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	454.0	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2010.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		29.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2010.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		31.0		36.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2010.0	F	Female		18.0	PT	Percent	E	Estimated	G	Global		9.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2000.0	M	Male		8.0	PT	Percent	E	Estimated	G	Global		6.0		9.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	716.0	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2010.0	F	Female		32.0	PT	Percent	E	Estimated	G	Global		28.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2000.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		29.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2000.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		29.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2010.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		30.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	426.0	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2010.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		33.0		37.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2010.0	M	Male		24.0	PT	Percent	E	Estimated	G	Global		16.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2000.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		21.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	566.0	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2010.0	F	Female		28.0	PT	Percent	E	Estimated	G	Global		21.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2010.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		29.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	686.0	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2010.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		30.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	100.0	Bulgaria	BGR	25.23763153	42.75731323	Europe and Northern America	2010.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		32.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	12.0	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2010.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		33.0		38.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		21.0		39.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	740.0	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2010.0	F	Female		28.0	PT	Percent	E	Estimated	G	Global		21.0		39.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2010.0	M	Male		32.0	PT	Percent	E	Estimated	G	Global		27.0		39.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	70.0	Bosnia and Herzegovina	BIH	17.78584332	44.16845548	Europe and Northern America	2010.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		30.0		39.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2000.0	F	Female		14.0	PT	Percent	E	Estimated	G	Global		12.0		18.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2010.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		25.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	854.0	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2010.0	F	Female		34.0	PT	Percent	E	Estimated	G	Global		27.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2000.0	M	Male		35.0	PT	Percent	E	Estimated	G	Global		29.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2000.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		30.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2010.0	M	Male		36.0	PT	Percent	E	Estimated	G	Global		31.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	233.0	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2010.0	F	Female		35.0	PT	Percent	E	Estimated	G	Global		31.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2000.0	F	Female		36.0	PT	Percent	E	Estimated	G	Global		32.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2000.0	M	Male		36.0	PT	Percent	E	Estimated	G	Global		32.0		40.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2000.0	F	Female		21.0	PT	Percent	E	Estimated	G	Global		15.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2010.0	F	Female		28.0	PT	Percent	E	Estimated	G	Global		19.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2010.0	M	Male		34.0	PT	Percent	E	Estimated	G	Global		26.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2010.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		26.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	222.0	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2010.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		26.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2000.0	M	Male		36.0	PT	Percent	E	Estimated	G	Global		30.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	894.0	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2010.0	F	Female		36.0	PT	Percent	E	Estimated	G	Global		32.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	188.0	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2010.0	M	Male		37.0	PT	Percent	E	Estimated	G	Global		33.0		41.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	152.0	Chile	CHL	-71.23029019	-35.2652885	Latin America and the Caribbean	2010.0	F	Female		39.0	PT	Percent	E	Estimated	G	Global		35.0		42.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2010.0	M	Male		17.0	PT	Percent	E	Estimated	G	Global		15.0		20.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2010.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		36.0		42.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	788.0	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2010.0	M	Male		28.0	PT	Percent	E	Estimated	G	Global		19.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	404.0	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2010.0	M	Male		35.0	PT	Percent	E	Estimated	G	Global		30.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2000.0	F	Female		38.0	PT	Percent	E	Estimated	G	Global		34.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2000.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		37.0		43.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	232.0	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2010.0	M	Male		33.0	PT	Percent	E	Estimated	G	Global		25.0		44.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2010.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		34.0		44.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	858.0	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2010.0	F	Female		38.0	PT	Percent	E	Estimated	G	Global		33.0		45.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2000.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		35.0		45.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2000.0	F	Female		39.0	PT	Percent	E	Estimated	G	Global		36.0		45.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2010.0	M	Male		42.0	PT	Percent	E	Estimated	G	Global		37.0		45.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2010.0	M	Male		40.0	PT	Percent	E	Estimated	G	Global		33.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2010.0	M	Male		41.0	PT	Percent	E	Estimated	G	Global		35.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	528.0	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2000.0	M	Male		42.0	PT	Percent	E	Estimated	G	Global		38.0		46.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	174.0	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2010.0	M	Male		23.0	PT	Percent	E	Estimated	G	Global		12.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2010.0	F	Female		36.0	PT	Percent	E	Estimated	G	Global		28.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	340.0	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2010.0	F	Female		39.0	PT	Percent	E	Estimated	G	Global		32.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	266.0	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2010.0	M	Male		39.0	PT	Percent	E	Estimated	G	Global		33.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	764.0	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2010.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		34.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2010.0	M	Male		42.0	PT	Percent	E	Estimated	G	Global		37.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	646.0	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2010.0	F	Female		42.0	PT	Percent	E	Estimated	G	Global		37.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	414.0	Kuwait	KWT	47.49305029	29.53949468	Northern Africa and Western Asia	2000.0	M	Male		43.0	PT	Percent	E	Estimated	G	Global		40.0		47.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2010.0	M	Male		29.0	PT	Percent	E	Estimated	G	Global		21.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2010.0	M	Male		44.0	PT	Percent	E	Estimated	G	Global		39.0		48.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	231.0	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2010.0	M	Male		38.0	PT	Percent	E	Estimated	G	Global		29.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	478.0	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2010.0	F	Female		42.0	PT	Percent	E	Estimated	G	Global		36.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2010.0	F	Female		44.0	PT	Percent	E	Estimated	G	Global		38.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	807.0	North Macedonia	MKD	21.7007909	41.60048068	Europe and Northern America	2010.0	F	Female		43.0	PT	Percent	E	Estimated	G	Global		38.0		49.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	192.0	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2010.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		30.0		50.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	528.0	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2000.0	F	Female		46.0	PT	Percent	E	Estimated	G	Global		42.0		50.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	148.0	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2010.0	F	Female		42.0	PT	Percent	E	Estimated	G	Global		34.0		51.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2000.0	M	Male		45.0	PT	Percent	E	Estimated	G	Global		39.0		51.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2010.0	M	Male		47.0	PT	Percent	E	Estimated	G	Global		42.0		52.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2000.0	M	Male		45.0	PT	Percent	E	Estimated	G	Global		38.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2010.0	M	Male		46.0	PT	Percent	E	Estimated	G	Global		39.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2000.0	F	Female		47.0	PT	Percent	E	Estimated	G	Global		42.0		53.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	703.0	Slovakia	SVK	19.48495604	48.70741446	Europe and Northern America	2010.0	F	Female		33.0	PT	Percent	E	Estimated	G	Global		26.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	203.0	Czechia	CZE	15.33151382	49.73913871	Europe and Northern America	2010.0	F	Female		49.0	PT	Percent	E	Estimated	G	Global		43.0		54.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	604.0	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2010.0	F	Female		40.0	PT	Percent	E	Estimated	G	Global		31.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2000.0	M	Male		47.0	PT	Percent	E	Estimated	G	Global		39.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2000.0	M	Male		48.0	PT	Percent	E	Estimated	G	Global		41.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	328.0	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2010.0	F	Female		49.0	PT	Percent	E	Estimated	G	Global		44.0		55.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2010.0	M	Male		49.0	PT	Percent	E	Estimated	G	Global		42.0		56.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	72.0	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2010.0	F	Female		52.0	PT	Percent	E	Estimated	G	Global		47.0		56.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	516.0	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2010.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		48.0		56.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2010.0	F	Female		46.0	PT	Percent	E	Estimated	G	Global		34.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	32.0	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2010.0	F	Female		52.0	PT	Percent	E	Estimated	G	Global		47.0		57.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2000.0	M	Male		49.0	PT	Percent	E	Estimated	G	Global		41.0		58.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	400.0	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2010.0	M	Male		51.0	PT	Percent	E	Estimated	G	Global		45.0		58.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	52.0	Barbados	BRB	-59.5346489	13.13648273	Latin America and the Caribbean	2010.0	F	Female		52.0	PT	Percent	E	Estimated	G	Global		46.0		58.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	620.0	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2010.0	F	Female		54.0	PT	Percent	E	Estimated	G	Global		47.0		60.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2010.0	M	Male		50.0	PT	Percent	E	Estimated	G	Global		43.0		61.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	116.0	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2010.0	F	Female		53.0	PT	Percent	E	Estimated	G	Global		46.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2000.0	F	Female		54.0	PT	Percent	E	Estimated	G	Global		47.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2010.0	F	Female		55.0	PT	Percent	E	Estimated	G	Global		49.0		62.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2010.0	F	Female		57.0	PT	Percent	E	Estimated	G	Global		50.0		63.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2010.0	F	Female		56.0	PT	Percent	E	Estimated	G	Global		50.0		63.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	204.0	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2010.0	F	Female		41.0	PT	Percent	E	Estimated	G	Global		27.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	554.0	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2010.0	M	Male		56.0	PT	Percent	E	Estimated	G	Global		47.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2000.0	F	Female		58.0	PT	Percent	E	Estimated	G	Global		51.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2000.0	F	Female		58.0	PT	Percent	E	Estimated	G	Global		52.0		64.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	688.0	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2010.0	M	Male		53.0	PT	Percent	E	Estimated	G	Global		39.0		65.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	442.0	Luxembourg	LUX	6.092656563	49.77679538	Europe and Northern America	2010.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		50.0		65.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2010.0	M	Male		58.0	PT	Percent	E	Estimated	G	Global		52.0		65.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	392.0	Japan	JPN	139.2716103	36.6554539	Eastern and South-Eastern Asia	2010.0	M	Male		57.0	PT	Percent	E	Estimated	G	Global		47.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2010.0	F	Female		60.0	PT	Percent	E	Estimated	G	Global		53.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	528.0	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2010.0	M	Male		61.0	PT	Percent	E	Estimated	G	Global		57.0		66.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	372.0	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2010.0	M	Male		60.0	PT	Percent	E	Estimated	G	Global		51.0		70.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2010.0	F	Female		63.0	PT	Percent	E	Estimated	G	Global		57.0		70.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2010.0	M	Male		62.0	PT	Percent	E	Estimated	G	Global		51.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2010.0	M	Male		62.0	PT	Percent	E	Estimated	G	Global		54.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	36.0	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2010.0	F	Female		63.0	PT	Percent	E	Estimated	G	Global		55.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2000.0	F	Female		63.0	PT	Percent	E	Estimated	G	Global		55.0		71.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	208.0	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2010.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		58.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	191.0	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2010.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		61.0		74.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2010.0	F	Female		66.0	PT	Percent	E	Estimated	G	Global		58.0		75.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2010.0	F	Female		68.0	PT	Percent	E	Estimated	G	Global		59.0		76.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2010.0	F	Female		67.0	PT	Percent	E	Estimated	G	Global		59.0		76.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2000.0	F	Female		66.0	PT	Percent	E	Estimated	G	Global		57.0		77.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2010.0	M	Male		65.0	PT	Percent	E	Estimated	G	Global		52.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	380.0	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2010.0	M	Male		67.0	PT	Percent	E	Estimated	G	Global		55.0		78.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2010.0	M	Male		72.0	PT	Percent	E	Estimated	G	Global		64.0		79.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	578.0	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2010.0	F	Female		74.0	PT	Percent	E	Estimated	G	Global		66.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2010.0	F	Female		75.0	PT	Percent	E	Estimated	G	Global		67.0		82.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	724.0	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2010.0	F	Female		76.0	PT	Percent	E	Estimated	G	Global		68.0		83.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2010.0	M	Male		63.0	PT	Percent	E	Estimated	G	Global		48.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	246.0	Finland	FIN	23.308447	61.91586738	Europe and Northern America	2010.0	F	Female		65.0	PT	Percent	E	Estimated	G	Global		50.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	276.0	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2000.0	M	Male		69.0	PT	Percent	E	Estimated	G	Global		57.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	528.0	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2010.0	F	Female		79.0	PT	Percent	E	Estimated	G	Global		75.0		84.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	642.0	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2000.0	F	Female		78.0	PT	Percent	E	Estimated	G	Global		70.0		86.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2000.0	M	Male		73.0	PT	Percent	E	Estimated	G	Global		60.0		88.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	250.0	France	FRA	2.457288129	46.62660861	Europe and Northern America	2010.0	M	Male		88.0	PT	Percent	E	Estimated	G	Global		71.0	>	95.0	2019.0
40.0	40.0	Access to anti-retroviral drug, by sex	34.0	Access to anti-retroviral drug, by sex	352.0	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2010.0	F	Female		94.0	PT	Percent	E	Estimated	G	Global		85.0	>	95.0	2019.0
